Avalo Therapeutics (AVTX) Competitors $4.78 -0.12 (-2.45%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$4.99 +0.21 (+4.29%) As of 07/11/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTX vs. SOPH, MNPR, SCPH, DSGN, VOR, ACIU, ESPR, PROK, KOD, and SLSShould you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include SOPHiA GENETICS (SOPH), Monopar Therapeutics (MNPR), scPharmaceuticals (SCPH), Design Therapeutics (DSGN), Vor Biopharma (VOR), AC Immune (ACIU), Esperion Therapeutics (ESPR), ProKidney (PROK), Kodiak Sciences (KOD), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry. Avalo Therapeutics vs. Its Competitors SOPHiA GENETICS Monopar Therapeutics scPharmaceuticals Design Therapeutics Vor Biopharma AC Immune Esperion Therapeutics ProKidney Kodiak Sciences SELLAS Life Sciences Group Avalo Therapeutics (NASDAQ:AVTX) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk. Which has stronger valuation & earnings, AVTX or SOPH? Avalo Therapeutics has higher earnings, but lower revenue than SOPHiA GENETICS. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$440K117.65-$35.13MN/AN/ASOPHiA GENETICS$65.17M3.57-$62.49M-$1.00-3.49 Is AVTX or SOPH more profitable? Avalo Therapeutics has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -98.51%. Avalo Therapeutics' return on equity of 111.00% beat SOPHiA GENETICS's return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A 111.00% 58.88% SOPHiA GENETICS -98.51%-63.47%-40.06% Do insiders & institutionals believe in AVTX or SOPH? 87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 3.0% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor AVTX or SOPH? In the previous week, Avalo Therapeutics had 1 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 3 mentions for Avalo Therapeutics and 2 mentions for SOPHiA GENETICS. Avalo Therapeutics' average media sentiment score of 0.94 equaled SOPHiA GENETICS'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SOPHiA GENETICS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, AVTX or SOPH? Avalo Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500. Do analysts recommend AVTX or SOPH? Avalo Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 527.62%. SOPHiA GENETICS has a consensus target price of $7.00, indicating a potential upside of 100.57%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Avalo Therapeutics is more favorable than SOPHiA GENETICS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00SOPHiA GENETICS 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryAvalo Therapeutics beats SOPHiA GENETICS on 10 of the 13 factors compared between the two stocks. Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTX vs. The Competition Export to ExcelMetricAvalo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.06M$2.74B$5.62B$9.10BDividend YieldN/A1.79%5.24%4.00%P/E RatioN/A9.4228.1020.27Price / Sales117.65714.12429.7099.23Price / CashN/A165.3637.4658.16Price / Book0.374.608.045.49Net Income-$35.13M$31.26M$3.18B$250.45M7 Day Performance-4.59%4.80%3.61%4.77%1 Month Performance-2.05%5.42%4.04%7.67%1 Year Performance-60.69%-4.36%29.99%16.38% Avalo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTXAvalo Therapeutics3.0147 of 5 stars$4.78-2.4%$30.00+527.6%-60.2%$53.06M$440K0.0040News CoverageSOPHSOPHiA GENETICS2.7436 of 5 stars$3.10+0.3%$7.00+125.8%-25.9%$206.06M$65.17M-3.10520Positive NewsMNPRMonopar Therapeutics2.0323 of 5 stars$35.78+6.5%$56.50+57.9%+924.0%$205.47MN/A-10.2810Analyst RevisionGap UpSCPHscPharmaceuticals4.5046 of 5 stars$3.81-1.6%$14.00+267.5%-4.8%$204.30M$36.33M-1.9930Positive NewsDSGNDesign Therapeutics0.6328 of 5 stars$3.37-5.6%$4.00+18.7%-7.5%$202.66MN/A-3.4040News CoveragePositive NewsVORVor Biopharma3.9171 of 5 stars$1.62+52.8%$5.63+247.4%+155.2%$202.44MN/A-0.98140Options VolumeHigh Trading VolumeACIUAC Immune2.251 of 5 stars$2.03+1.0%$12.00+491.1%-42.5%$201.82M$31.02M-3.50140Analyst RevisionESPREsperion Therapeutics4.0385 of 5 stars$0.98-0.9%$7.00+611.1%-52.2%$196.93M$332.31M-1.23200News CoveragePositive NewsAnalyst RevisionPROKProKidney2.664 of 5 stars$0.59-11.5%$3.50+491.1%+89.2%$195.73M$80K-0.993News CoverageAnalyst ForecastInsider TradeGap DownHigh Trading VolumeKODKodiak Sciences4.0934 of 5 stars$3.73+0.8%$9.00+141.3%+64.1%$195.23MN/A-1.0390News CoverageSLSSELLAS Life Sciences Group0.3428 of 5 stars$2.19+12.3%N/A+60.0%$194.57M$1M-5.7610High Trading Volume Related Companies and Tools Related Companies SOPHiA GENETICS Competitors Monopar Therapeutics Competitors scPharmaceuticals Competitors Design Therapeutics Competitors Vor Biopharma Competitors AC Immune Competitors Esperion Therapeutics Competitors ProKidney Competitors Kodiak Sciences Competitors SELLAS Life Sciences Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTX Stock Alerts